Dizal (Jiangsu) Pharmaceutical Co., Ltd.

SHSE:688192 Stock Report

Market Cap: CN¥18.7b

Dizal (Jiangsu) Pharmaceutical Valuation

Is 688192 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688192 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688192 (CN¥45.1) is trading below our estimate of fair value (CN¥165.29)

Significantly Below Fair Value: 688192 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688192?

Key metric: As 688192 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688192. This is calculated by dividing 688192's market cap by their current revenue.
What is 688192's PS Ratio?
PS Ratio48.1x
SalesCN¥389.64m
Market CapCN¥18.75b

Price to Sales Ratio vs Peers

How does 688192's PS Ratio compare to its peers?

The above table shows the PS ratio for 688192 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average26.4x
688520 Sinocelltech Group
6.9x28.0%CN¥16.8b
688062 Mabwell (Shanghai) Bioscience
52.8x87.8%CN¥8.9b
688266 Suzhou Zelgen BiopharmaceuticalsLtd
34.7x59.6%CN¥17.0b
688278 Xiamen Amoytop Biotech
11.2x29.0%CN¥29.2b
688192 Dizal (Jiangsu) Pharmaceutical
48.1x45.1%CN¥18.7b

Price-To-Sales vs Peers: 688192 is expensive based on its Price-To-Sales Ratio (48.1x) compared to the peer average (26.4x).

Price to Sales Ratio vs Industry

How does 688192's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
603716 Thalys Medical Technology Group
0.8xn/aUS$211.90m
No more companies available in this PS range
688192 48.1xIndustry Avg. 7.5xNo. of Companies8PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 688192 is expensive based on its Price-To-Sales Ratio (48.1x) compared to the CN Biotechs industry average (7.5x).

Price to Sales Ratio vs Fair Ratio

What is 688192's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688192 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio48.1x
Fair PS Ratio21.5x

Price-To-Sales vs Fair Ratio: 688192 is expensive based on its Price-To-Sales Ratio (48.1x) compared to the estimated Fair Price-To-Sales Ratio (21.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688192 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥45.10
CN¥56.00
+24.2%
3.6%CN¥58.00CN¥54.00n/a2
Apr ’25CN¥43.60
CN¥52.16
+19.6%
3.5%CN¥54.00CN¥50.31n/a2
Mar ’25CN¥37.25
CN¥52.16
+40.0%
3.5%CN¥54.00CN¥50.31n/a2
Feb ’25CN¥32.17
CN¥52.16
+62.1%
3.5%CN¥54.00CN¥50.31n/a2
Jan ’25CN¥47.85
CN¥57.73
+20.7%
13.9%CN¥68.89CN¥50.31n/a3
Dec ’24CN¥46.65
CN¥57.73
+23.8%
13.9%CN¥68.89CN¥50.31n/a3
Nov ’24CN¥42.76
CN¥57.73
+35.0%
13.9%CN¥68.89CN¥50.31CN¥48.143
Oct ’24CN¥35.48
CN¥57.73
+62.7%
13.9%CN¥68.89CN¥50.31CN¥43.823
Sep ’24CN¥32.71
CN¥57.73
+76.5%
13.9%CN¥68.89CN¥50.31CN¥37.653
Aug ’24CN¥36.09
CN¥56.42
+56.3%
13.0%CN¥68.89CN¥50.31CN¥39.344
Jul ’24CN¥34.70
CN¥56.42
+62.6%
13.0%CN¥68.89CN¥50.31CN¥35.944
Jun ’24CN¥44.87
CN¥56.42
+25.7%
13.0%CN¥68.89CN¥50.31CN¥39.454
May ’24CN¥53.55
CN¥51.40
-4.0%
2.1%CN¥52.48CN¥50.31CN¥45.052
Apr ’24CN¥42.37
CN¥51.40
+21.3%
2.1%CN¥52.48CN¥50.31CN¥43.602
Mar ’24CN¥48.34
CN¥51.40
+6.3%
2.1%CN¥52.48CN¥50.31CN¥37.252
Feb ’24CN¥51.78
CN¥51.40
-0.7%
2.1%CN¥52.48CN¥50.31CN¥32.172
Jan ’24CN¥39.37
CN¥50.63
+28.6%
3.7%CN¥52.48CN¥48.78CN¥47.852

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

7D

-2.6%

1Y

13.6%